Concepedia

Author

Sabrina Baltschukat

Novartis (Switzerland)ORCID

Also Known As

Sabrina Baltschukat

17

Publications

825

Citations

5

H-Index

15

Concepts

All Affiliations

Novartis (Switzerland)
SB

About

Sabrina Baltschukat is an author at Novartis (Switzerland) specializing in targeted therapy, cancer research, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Engineering

1

1

14

2

Medicine

1

1

14

3

Cell Biology

1

1

14

4

Cancer Therapeutics

1

1

14

5

Gene Editing

1

1

14

Sabrina Baltschukat

×

4

Publications

816

Citations

4

H-Index

YearCitations

Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma

Lipika Goyal, Supriya K. Saha, Leah Y. Liu,

Cancer Discovery

2016

527

Capmatinib (INC280) Is Active Against Models of Non–Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation

Sabrina Baltschukat, Barbara Schacher Engstler, Alan Huang,

Clinical Cancer Research

2019

171

Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers

Emilie A. Chapeau, Laurent Sansregret, Giorgio Giacomo Galli,

Nature Cancer

2024

104

Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors

Ralph Tiedt, Frederick J. King, Christelle Stamm,

Cell Reports

2023

14

Page 1